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ABSTRACT 
BACKGROUND: Pain is the most common ailment around the world, according to the 
American Academy of Pain Medicine; 100 million Americans suffer with chronic pain, 
which is more than any other main disorder and is described by more than 60% as 
impacted their overall enjoyment of life (AAPA). The ketogenic diet (KD) is a high fat, 
low carbohydrate dietary regimen, which is described to decrease neuronal excitation, 
increase ketone bodies and ATP levels, while lowering glucose and proinflammatory 
cytokines. The KD is an effective therapy for epilepsy; a disorder that arises from either 
lowered inhibition or increased excitation, similar to pain. The goal of the current study 
is to establish whether the KD is effective in lowering inflammatory pain in a rat. 
  
METHODS: We investigated whether a strict KD decreases inflammatory pain in adult 
male rats. Rats were maintained on either the KD or a standard diet for two to four 
weeks. We obtained both physiological measure and behavioral measures before and 
after being injected in the right hind paw with heat-killed tuberculosis bacteria (CFA) to 
cause inflammation. Physiological measures included weight, paw volume, paw 
weight, blood ketone and blood glucose levels. Tactile sensitivity and spontaneous pain 
was used to assess behavioral pain. 
 
RESULTS: Ketones were increased in rats after the KD. Our results indicate that the KD 
may alleviate pain, as there were significant changes indicating lowered swelling from 
the right paw weight. Paw volume indicated a trend leading us to believe that there 
may be significance if there were more rats. This was similarly seen in the tactile 
sensitivity, where there was a trend of KD having lowered pain at 4 hours post-injection 
compared to CD. Spontaneous pain and myeloperoxidase had no significant changes 
between the KD and CD groups. 
 
CONCLUSION: The data suggest that KD may alleviate pain as there is a lower 
inflammatory swelling and a trend towards decreased pain sensitivity. Future research 
will aim to elucidate whether there is an effect of the KD on inflammatory pain by using 
lower amounts of CFA and earlier spontaneous pain testing. 
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INTRODUCTION  
PAIN 
Background 
 Pain can be described as a sensory and/or emotional experience that results from 
physical damage such as tissue injury or nonphysical damage such as emotional pain. 
Pain is often considered a symptom of another illness and, while often true, pain has a 
variety of causes and is not fully understood mechanistically. Pain has been classified 
into various categories but most frequently for clinical assessment and treatment it is 
separated into: nociceptive, neuropathic, and inflammatory pain (Pain Management, 2010). 
This classification illustrates the massive scope the term pain encompasses. These three 
categories, defined in detail below, are defined by the location of the area affected. 
Researchers believe that there is not one mechanism, which encompasses all three types 
of pain. Rather it is commonly believed that there is a combination of several 
mechanisms that cause pain, as it is well known that inflammatory mechanisms are 
involved in neuropathic pain. 
 Pain is the most common ailment around the world, a recent study states that 
more than 1.5 billion people suffer from chronic pain while 3-4.5% suffer from 
neuropathic pain (Global Industry Analysts, 2011). Throughout history there has been a 
multitude of methods to treat and understand pain, however there has still been no 
treatment to successfully treat all types of pain. It is necessary thus to find a safe and 
effective treatment to alleviate individuals suffering with unrelenting or undertreated 
pain.  
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Treatment and Prevalence  
 Pain embodies a wide range of conditions including arthritis, migraines, spinal 
injuries, cancer, neuropathic pain, and others.  
 According to the American Academy of Pain Medicine, 100 million Americans 
suffer with chronic pain, more than any other main disorder. The survey study on 
chronic sufferers revealed that roughly 60% reported that the chronic pain impacted 
their overall enjoyment of life (American Pain Foundation, 2006). A survey conducted 
by the American Pain Foundation (2006) on approximately 300 chronic pain sufferers 
found that more than half felt they had no control over their pain. Individuals with 
severe pain have trouble concentrating, they report that their energy level is impacted, 
and many report an inability to get restful sleep (Niels Becker et al., 1997). These 
individuals run a risk of developing various comorbidities, may not receive pain relief 
from medication, and due to cost of medication may develop a financial burden. In the 
United States the total annual cost of health care due to pain was between $560-635 
billion in 2010 (National Academies Press, 2011). 
 Chronic pain is frequently comorbid with other psychiatric diseases most often 
with panic disorder, post-traumatic stress disorder and depression (McWilliams, Cox & 
Enns, 2003). Treatment for chronic pain typically includes NSAIDs, opioids, 
antiepileptic drugs, and antidepressants. The use of over-the-counter and prescription 
drugs for both acute and chronic pain is very common in Western culture and yet it is 
less than ideal as it has several downfalls: it can cause tolerance, dependence and 
addiction, and it does not always provide the relief necessary to live a normal life. 
Prescription drug abuse has increased substantially from 1998 to 2008, and is 
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considered to be a major contributor to drug deaths (SAMHSA, 2010; CDC, 2010). 
Individuals may not respond positively to pain medicine due to genetic mutations that 
alter their drug metabolism or may suffer from other issues such as addiction or 
tolerance.  
 There is a necessity for more research to understand pain. Recent research has 
linked the ketogenic diet as providing analgesic effects with little or no side effects. Pain 
affects individuals’ in physical, psychological and economical. Finding an effective and 
efficient way to manage pain is vital to decrease the burden it places on families and 
society. 
 
Pain Etiology  
 The pathophysiology of pain has not been completely elucidated, however it is 
hypothesized that pain is linked to over-excited nerves. Over-excited nerves can arise as 
a result of glutamate-induced excitotoxicity, increased glutamatergic receptors, or 
decreased GABA or GABA receptors. Individuals with psychological illnesses such as 
major depression, somatization disorder and hypochondriasis are much more likely to 
develop a chronic pain disorder. This connection suggests that there is a common factor 
among these disorders heightening the probability of comorbidity with pain.  
 Pain typically arises from injury, inflammation and/or disease and is 
perpetuated by the interplay of stress responses, deregulated injury signaling and 
negative emotions. Pain can be beneficial when it acts as a warning but can cause a 
deleterious impact when it is extended. There are multiple types of pain each with 
commonalities and differences in the way they are derived and understood.  
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 As mentioned above the three common types of pain are nociceptive, neuropathic 
and inflammatory. Here each is discussed briefly related to the etiology of pain. 
Nociceptive pain results from exposure to external stimuli, these neurons express a 
multitude of ion channels. Changes in these channels can affect the processing of pain. 
Neuropathic pain is a result of tissue damage or disease, which can damage nerve fibers 
causing pain. Sensory processing abnormality is often altered and individuals may 
report hyperalgesia, increased pain sensitivity, or allodynia, a condition where non-
painful stimuli cause pain. Inflammatory pain involves the interplay between the 
immune system and the central nervous system. 
 Injury, inflammation and disease can all alter neuronal structure by altering 
neurotransmitters (inter-neuronal chemical messenger), receptors (a protein which in 
the presence of specific neurotransmitters transmits a signal to a neuron), ion channels 
(protein which allows for an influx or efflux of ions in the cell), and connections 
(number of synaptic terminals) (Stucky, Gold & Zhang, 2001). It is hypothesized that 
pain is either a result from increased excitatory or decreased inhibitory activity 
(discussed below; Stucky, Gold & Zhang, 2001).  
 
Inflammatory Pain 
 This study will focus on inflammatory pain and thus the rest of this section is 
dedicated to the etiology of inflammatory pain. Inflammatory pain can result from both 
endogenous and exogenous stressors. This change in activity alters the release of 
various mediators including proinflammatory cytokines (IL-1-alpha, IL-1-beta, IL-6 and 
TNF-alpha), chemokines, reactive oxygen species, vasoactive amines, lipids, ATP, acid, 
and other factors (Focus on Pain, 2014). These regulators are typically released by 
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infiltrating leukocytes, vascular endothelial cells, or tissue resident mast cells (Focus on 
Pain, 2014).  
 Sensory information arising from an inflammation typically activates afferent 
neurons; this signal is relayed to the thalamus and brainstem (Kidd & Urban, 2001). In 
the beginning stages of inflammation, studies have shown that prostaglandins and 
bradykinin alter the sensitivity of receptors and reduce the excitatory threshold of 
neurons (Dray, 1995). Long-term changes due to inflammation occur via cytokines and 
growth factors causing transcriptional changes such as increasing receptors, ion 
channels and/or neurotransmitters (Woolf & Costigan, 1999). High stimulus intensity 
due to tissue damage induces substance P, which increases NMDA receptors and is 
linked to higher activation via glutamate (Kidd & Urban, 2001). Thus, it is believed that 
the underlying principal in pain is that the threshold for excitation is lowered, 
producing more neuronal firing. Furthermore, substance P is secreted by nerves and 
inflammatory cells and ultimately has been shown to have proinflammatory effects in 
immune and epithelial cells (O’Connor et al., 2004). 
 Inflammatory pain is typically manifested by pain, heat, redness and swelling 
(Maroon, Bost & Maroon, 2010). Pain is considered to arise most frequently from 
inflammation, which is the type of pain we focus on in this thesis. Current 
pharmacological intervention for inflammatory pain consists of non-steroidal anti-
inflammatory drug (NSAID), which are able to interfere with the inflammatory cascade 
through inhibiting the production of prostaglandin (Talalay & Talalay, 2001). However, 
NSAIDs medication has significant side effects and finding alternatives to reducing 
pain and inflammation would be highly beneficial for many individuals. It has long 
been known that fasting is anti-inflammatory, however, fasting can be extremely hard 
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and potentially dangerous for individuals to adhere to (Shibolet et al., 2002). The 
ketogenic diet is a dietary regimen, which has been found to mimic fasting and is 
suspected to help reduce pain and inflammation, which is further discussed below. 
 
KETOGENIC DIET 
Background 
 The ketogenic diet (KD) is a high fat, adequate protein, low carbohydrate 
metabolic therapy that has been used to effectively treat epilepsy (Danial et al., 2013). 
The KD was first recognized by the American Medical Association in 1921 in which Dr. 
Rawle Geyelin presented the story of Dr. H.W. Conklin who treated his epileptic 
patients with intermittent starvation and found cure rates up to 90% (Bailey, Pfeifer & 
Thiele, 2004). Wilder and Winter at the Mayo Clinic were the first to suggest that the 
effects of altering metabolism may be a result from the presence of ketone bodies and 
proposed a diet with a higher fat and lower carbohydrate content (Bailey, Pfeifer & 
Thiele, 2004). The KD mimics the fasting diet originally found to alleviate epileptic 
seizures. This dietary regimen has since proven to successfully lower seizure rates in 
both children and adults (Freeman, Kossoff, & Hartman, 2007). However, in the 1940s 
anticonvulsants were introduced, and the popularity of the KD fell out of favor. The KD 
was difficult to maintain compared to pharmaceutical interventions such as 
anticonvulsants. Despite challenges in implementing the KD it has remained a powerful 
treatment for epilepsy even when anticonvulsants fail. Recent studies suggest that the 
KD may be effective in alleviating both psychiatric and physiological diseases. Research 
on the KD is still limited, and a large gap remains on understanding the mechanism of 
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action. However, drugs that treat epilepsy are often prescribed for pain, suggesting that 
epilepsy and pain may share molecular elements. 
 
Biochemical Pathway of the Ketogenic Diet 
 The KD reduces carbohydrate consumption while increasing fat intake 
ultimately lowering glucose 
metabolism and increasing fat 
metabolism. The entire mechanism of 
the KD is still unknown, but it is well 
known that KD allows for the 
breakdown of fatty acids in the liver which is the exported to extra-hepatic sites 
including the brain. The mitochondria in the liver converts β-oxidation-derived acetyl-
CoA to ketones via mitochondrial thiolase, HMG-CoA synthase, and HMG-CoA lyase 
(Danial et al., 2013). The ketone bodies (acetone, acetoacetate, β-hydroxybutyrate) 
provide an alternative energy source (fig.1) (Danial et al., 2013).  
The formation of ketone bodies occurs naturally at a slow level to provide energy 
to certain organs (particularly the brain) or in fasting or exercise. Ketosis occurs when 
glucose levels are low, glycogen levels are depleted and thus fatty acids are 
metabolized. Fatty acids are β-oxidized into acetyl-CoA, which would typically proceed 
to the tricarboxylic acid (TCA) cycle and would in turn drive the electron transport 
chain for ATP synthesis. The KD lowers glucose intermediates such as oxaloacetate 
causing fatty acid levels to exceed the metabolic capacity of the TCA cycle. The 
Figure	1.	Ketone	Body	Synthesis	from	Acetyl-CoA	
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increased level of acetyl-CoA promotes the formation of ketone bodies, noted above are 
water-soluble molecules that can be used as an energy source throughout the body, 
including the brain (Masino & Rho, 2012). Ketone bodies are more efficient at making 
ATP than glucose. Veech (2004) describes that due to a higher heat of combustion in D-
β-hydroxybutyrate there is a 28% increase in hydraulic efficiency compared to pyruvate, 
the end product of glycolysis. Ketones can be synthesized to produce fatty acids in the 
brain, which provide essential building blocks for biosynthesis of cell membranes and 
other lipids (Danial et al., 2013). Mechanisms of how the KD is thought to affect the 
body are described in a later section.  
 
Dietary Regimen 
The KD is a strict dietary regimen that must be maintained to elicit therapeutic 
benefits. The “classic” KD is typically described as a ratio of 4:1 of fats to carbohydrates 
+ to protein (Zupec-Kania & Spellman, 2008). Ketosis is typically reached after 72 hours 
on the diet and when glucose levels are between 55-75 mg/dL and ketone levels range 
between 4-10 mmol (Zupec-Kania & Spellman, 2008). The “classic” KD uses long-chain 
triglygerides (LCT), which are 12-18 carbons in length and the predominant fat in the 
American diet (Bach, Frey & Lutz, 1989). A meal on the “classic” KD may consist of 
broccoli cooked in butter and ground beef cooked in a cream sauce. The “classic” KD 
has a very high fat content and can be difficult to adhere to.  
The modified KD was introduced as a more palatable alternative to the “classic’ 
KD. The modified KD uses medium-chain triglycerides (MCT), which are composed of 
6 to 10 carbons (Bach, Frey & Lutz, 1989). MCTs are hydrolyzed more efficiently in the 
body than LCTs, producing more ketones per calorie (Kossoff, Zupec-Kania & Rho, 
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2009). MCTs when metabolized to fatty acids are able to cross into the mitochondrial 
membrane without the use of a transporter, and thus more quickly converted to fuel 
(Bach, Frey & Lutz, 1989). The modified KD allows for more proteins and carbohydrates 
ultimately making it more palatable: a typical meal may be brown rice, a salad with 
vegetables, and chicken cooked in oil.  
Coconut oil is an inexpensive MCT that has been receiving a lot of attention for 
its multitude of beneficial effects. Furthermore, MCTs have been speculated at 
enhancing the immune system (Bach, Frey & Lutz, 1989). Kono and colleagues (2000) 
found that MCTs prevented alcohol-induced liver injury in rats by inhibiting reactive 
oxygen species and TNF-α. TNF-α is a pro-inflammatory cytokine. Due to reduced fat 
and increased food choice and variety the modified KD is a more palatable dietary 
regimen that has been found to be just as affective as the “classical” KD.  
Dietary treatments such as the KD have long been used as a strategy to combat 
various clinical conditions. The KD is predominantly used as a treatment for epilepsy, 
however evidence is growing that the KD could be effective in treating a wide range of 
diseases and disorders (table 1) (Kossoff, Zupec-Kania & Rho, 2009). 
Table 1. Uses of the Ketogenic Diets Published in Literature 
(Adapted from Barañano & Hartman, 2008) 
Human Studies 
- Seizures (epilepsy) 
- Metabolic Defects (PDH and PFK 
deficency, and glycogenosis type V) 
- Reduced Astrocytomas 
- Neurological disorders (AD & PD) 
- Autism 
- Migraines and Narcolepsy 
- Glioblastoma multiforme 
Animal Studies 
- Tumors Reduction (gliomas, 
prostate cancer, gastric cancer) 
- Protects against Truma and 
ischemia 
- Neurological disorders (AD & PD) 
- ALS 
- Depression 
- Autism 
 
Table	1.	The	table	above	outlines	different	disorders	that	have	been	studied	on	the	KD	in	either	a	human	or	rodent	subjects.	The	italicized	have	little	concrete	research	or	clinical	studies	in	progress.		
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The worldwide use of the KD has increased with now 73 academic centers in 41 
countries advocating it as a therapeutic approach to various illnesses (Kossoff & 
McGrogan, 2005).  
 
Ketogenic Diet mechanism of action 
 The mechanism of action in the KD is still poorly understood, but it has been 
linked to reduced neuronal excitability, described below. It is unknown whether the 
reduced neuronal excitability is caused directly by an increase in ketone bodies and/or 
a decrease in glucose or the result of another mechanism (Ruskin & Masino, 2012). The 
potential mechanisms are outlined below (Table 2). There is likely a complex interplay 
of different networks including the biochemical and physiological systems 
consequently it may be a combination of more than one mechanism that provides some 
of the alleviating affects we have seen in the KD. Once this mechanism is understood 
there are opportunities of easily accessing the vast benefits of the KD without adhering 
to the constraints of the diet.  
Table 2. KD Hypothesis for Mechanisms of Action 
• Ketone Hypothesis (Glucose Hypothesis) 
• Adenosine Theory 
• Anti-inflammatory and Lowered Reactive Oxygen Species 
• Metabolic hypothesis 
• Amino Acid Hypothesis 
 
The KD can decrease neuronal excitation, reduce reactive oxygen species, 
increase adenosine, produce hypoglycemia, alter inflammatory cytokines and 
Table	2.	The	table	above	outlines	the	five	most	common	KD	hypotheses.	
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reduce swelling after experimental inflammation (Merry, 2004; Maalouf et al., 
2009). The following section elaborates on these mechanisms and how they may 
underly effects of the KD. 
• The ketone hypothesis predicts that the ketone bodies have a direct 
anticonvulsant effect (Nylen, Likhodii, & Burnham, 2009). Ketone bodies 
form in excess under low carbohydrate and increased glucose, thus this 
hypothesis is closely linked to lowered glucose intake from the KD. 
Acetone, a ketone body, has been shown to have anticonvulsant effects 
however the specific mechanism is unknown, it is speculated to act 
through voltage-gated potassium channels (Masino & Rho, 2012). Juge 
and his colleagues (2010) recently discovered a link between ketone bodies 
and neuronal excitability. They determined that acetoacetate, a ketone 
body, inhibits vesicular glutamate transporters (Juge et al., 2010). Juge and 
colleagues (2010) found that ketone bodies compete with chloride ions, 
which act as an allosteric activator on the vesicular-glutamate transporter. 
These transporters are required for the storage of the excitatory 
neurotransmitter glutamate in vesicles, for later synaptic release. Lowered 
synaptic glutamate means lowered neuronal excitability, thereby lowering 
the occurrence of seizures. Furthermore, both acetone and β-
hydroxybutyric acid enhance GABA receptor function, illustrating the 
there is increased inhibition (Yang et al., 2007). Individuals with 
depression have too much glutamate in their synapses thus the glucose 
hypothesis offers a potential therapeutic approach for depression; this link 
is being researched further (Sanacora, Treccani & Popoli, 2012). 
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• The adenosine hypothesis predicts that the KD increases adenosine, which 
inhibits neuronal excitability through adenosine A1 receptors (A1Rs) 
(Masino et al. 2009). Adenosine is a neuromodulatory purine; it has been 
shown in vivo and in vitro that KD feeding reduces seizure and seizure like 
activity via A1Rs (i.e. KD effects were blocked by pharmacological or 
genetic A1R inactivation) (Masino et al. 2011; Kawamura et al., 2014). The 
in vitro studies demonstrated that KD-related adenosine was derived from 
the break down of ATP (core of the ATP molecule) (Masino et al. 2011; 
Kawamura et al., 2014). This ATP was released from intracellular stores 
from pannexin channels (Masino et al. 2011; Kawamura et al., 2014). The 
KD is known to increase ATP levels in the brain (Pan et al. 1999). 
•  A low carbohydrate high fat diet was shown to significantly reduce 
proinflammatory cytokines and reactive oxygen species. Proinflammatory 
cytokines including TNF-α, IL-6, MCP-1, E-selectin, I-CAM, and PAI-1 
were reduced on a KD compared to a low fat diet (Forsythe et al., 2007). 
Lowering proinflammatory cytokines is beneficial in a vast number of 
diseases and disorders. Ruskin et al. (2009) found that the KD reduces 
experimental inflammation as measured by paw swelling and plasma 
extravasation. A diet that forces fats to be metabolized reduces the amount 
of superoxide produced from the electron transport chain, because the 
beta-oxidation allows for the by-pass of the mechanism that converts 
glucose to pyruvate (Veech, 2004). This would ultimately reduce the 
reactive oxygen species throughout the body (Manninen, 2004). Reactive 
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oxygen species at high concentrations are detrimental to cells and cause 
apoptosis, whereas evidence suggests reducing reactive oxygen species is 
beneficial for the body and mind.  
• The metabolic hypothesis proposes that the KD is more efficient at 
providing energy to the brain (Nylen, Likhodii, & Burnham, 2009). Ketone 
bodies produce more ATP per unit than glucose (elevated ATP production 
reactive oxygen species, which actually argues against the anti-
inflammatory hypothesis above). Furthermore Bough et al. (2006) 
reported that the KD increases the number of mitochondria in a rat. Many 
neurological disorders have dysfunctional mitochondria, and thus the KD, 
which increases their number and efficiency, measured via electron 
microscopy, with the extra energy from ketone bodies, is ultimately able 
to improve metabolic function and provide therapeutic relief.  
• The fifth hypothesized mechanism is the amino acid theory, which 
suggests that the KD modifies the balance of amino acid neurotransmitters 
in the brain. When the brain changes from glucose to ketone body 
metabolism the ratio of glutamate to GABA decreases, increasing 
GABAergic inhibition.  
 Overall the KD is postulated to decrease neuronal excitation by increasing 
ketone bodies and ATP levels and lowering glucose and proinflammatory 
cytokines. The KD was also found to increase adenosine and GABA, both 
inhibitory neuromodulators, and decrease glutamate, an excitatory 
neuromodulator (Masino and Geiger, 2008; Omote et al., 2011; Juge et al., 2010). 
		 	
		 20	
 
PROPOSED CONNECTION- Ketogenic Diet and Pain  
As noted, the KD is thought to increase inhibition and/or decrease 
excitation. The KD is an effective therapy for epilepsy; a disorder that arises from 
either lowered inhibition or increased excitation, similar to pain. Studies suggest 
that the KD can be used for pain relief and lowering inflammation. The following 
evidence described below illustrates converging evidence of the likely effects of 
the KD influencing pain and inflammation. Masino and Ruskin (2013) describe 
four postulated mechanisms of the reasoning behind the therapeutic affects of 
the KD and pain and inflammation (table 3). 
Table 3. Ketogenic Diet, Pain and Inflammation: Postulated 
Mechanisms (Masino & Ruskin, 2013) 
 
Masino and Ruskin (2013) highlight studies relating high fat and low 
carbohydrate diets to the perception and inflammation of pain; together these 
studies suggest a link between these two areas, consistent with postulated 
mechanisms. These are discussed in detail below. 
• Epilepsy and pain have been described as complex conditions that have 
diverse underlying conditions but both seem to have overexcited nerves. 
1. Reduces excitatory and/or increases inhibitory mechanisms 
2. Fewer reactive oxygen species has anti-inflammatory effects 
3. Adenosine has anti-inflammatory effects  
4. Reducing glycolytic metabolism is analgesic  
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It is presumed that a treatment that can reduce the excitability of nerves 
would be a good therapy for pain. Anticonvulsants drugs are often used 
for neuropathic pain, further exemplifying that if the KD decreases 
excitatory or increases inhibitory mechanisms in epilepsy then it could 
produce the same affect in pain (Masino & Ruskin, 2013). 
• Reactive oxygen species are a major component of inflammation, and as 
noted previously the KD reduces reactive oxygen species. Exogenous 
ketones were shown to reduce reactive oxygen species both in vitro and in 
vivo (Kim, Vallejo & Rho, 2010; Masino & Ruskin, 2013). Thus, a diet such 
as the KD that alter the metabolism and creates increased levels of ketones 
could be expected to reduce reactive oxygen species. Reactive oxygen 
species are linked to numerous diseases and disorders, specifically 
Wiseman and Halliwell (1996) describe that reactive oxygen species have 
been increasingly linked to inflammatory disease as well as cancer. The 
KD was found to reduce reactive oxygen species in the brain and 
ultimately reduce inflammation in a model of multiple sclerosis and in 
individuals with liver disease (Kim et al., 2012; Tendler et al., 2007).  
• Adenosine levels are increased on the KD and adenosine has long been 
implicated in reducing inflammation and pain, by inhibiting neuronal 
excitability through the A1Rs (Masino et al., 2009).  Schmidt et al. (2009) 
determined, that allopurinol, a non-selective adenosine-receptor that 
increases adenosine levels induced anti-nociception.  
• Reducing glycolytic metabolism is hypothesized to be another mechanism 
that provides a decrease in excitatory and/or increase in inhibitory 
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mechanisms. One study found that children on a MCT diet who had their 
seizures under control when given an infusion of glucose their seizures 
quickly returned (Huttenlocher, 1976). As discussed previously, pain is 
related to overly excited neurons and thus if reducing glucose is inhibitory 
it is expected to lower pain Furthermore when 2-deoxy-D-glucose, which 
blocks glycolysis, was found to have anticonvulsant effects (Bodnar et al., 
1979).  
The described mechanisms above suggest a link that should be further analyzed 
between the KD and different types of pain. Our lab found that an acute model 
of pain using thermal pain had an increased thermal pain sensitivity when on the 
KD compared to control rats (Ruskin et al., 2013). These effects were reversed 
once the KD rats were placed on the control diet (Ruskin et al., 2013). 
Furthermore, our lab has studied the relationship between the KD and 
inflammatory pain. One study used local inflammation into the hindpaw with 
complete Freund’s adjuvant to examine swelling and plasma extravasation in 
juvenile and adult rats (Masino & Ruskin, 2013). Juvenile rats had significantly 
reduced levels of these two types of inflammation when on the KD; these results 
were less but still significant in adults (Masino & Ruskin, 2013). Another study 
on neuropathic pain used the antimitotic cancer drug in which rats were on the 
KD prior to injection (Masino & Ruskin, 2013). The study found reduced 
mechanical pain sensitivity on rats fed a strict 6:6:1 diet at the 8-day time point 
(Masino & Ruskin, 2013). Another study by Piomelli and Sasso (2014) found that 
an increasing number of lipid molecules are able to suppress the inflammatory 
process, restore homeostasis in damaged tissue, and attenuate pain sensitivity by 
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regulating the peripheral nervous system. One study regarding pain and the KD 
showed a strong trend towards the KD alleviating pain (Yancy et al., 2009). This 
research suggests that there should be more research to determine whether a 
strong relationship exists between different types of pain and the KD. 
Overall pain is a prevalent and challenging disorder and there are many 
individuals with unrelenting or unmet need for treatment of pain and 
inflammation. The KD or a metabolic therapy would be a platform that 
individuals all around the world could use to tackle their pain. Here we study 
this intersection between these two fields of research and test the effects of a KD 
on inflammatory pain.  
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Thesis Overview and Hypothesis 
 The current study aims to test the hypothesis that a ketogenic diet will 
reduce inflammatory pain. This study will help gather evidence whether the 
ketogenic diet could be used as a therapy for individuals experiencing pain and 
reducing inflammation. In the present study we use both behavioral and 
inflammatory markers to analyze rats on a strict ketogenic diet versus rats on a 
normal chow after they are injected with CFA (complete Freund’s adjuvant) in 
their right hind paw to cause persistent inflammation. 
 We expect one of two scenarios: inflammation and inflammatory pain are 
lowered or only inflammatory pain is lowered. If inflammation and 
inflammatory pain were lowered on the ketogenic diet, it suggests that the 
ketogenic diet reduces inflammatory pain by reducing inflammation. 
Alternatively, if the behavior indicates less pain but there is no significant change 
in the inflammation, it would suggest this alleviation occurs through an anti-
nociceptive mechanism. 
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METHODS 
Ethics Statement 
 Procedures were followed according to the NIH Guide for the Care and 
Use of Laboratory Animals and were approved by the Animal Care and Use 
Committee of Trinity College (A3869-01). 
Animals and Method Overview 
 Male Sprague-Dawley rats were fed a standard chow diet until eight 
weeks of age. Two to three rats were housed together in cages with water and 
enrichment toys and kept on a 12 hr light-dark cycle. At eight weeks, half the rats 
were switched onto a ketogenic diet (KD) (F3666; BioServ, Frenchtown, NJ) for 
two or four weeks while the other half remained on a standard chow diet (SD). 
The KD was a “classic” research formulation with a ketogenic ratio of 6:1. All 
testing occurred two or four weeks after the dietary treatment, at which point 
rats were 10-16 weeks of age.  
 Behavior tests consisted of spontaneous pain and tactile sensitivity and 
were conducted before and after being injected in one hind paw with heat-killed 
tuberculosis bacteria (CFA) that causes persistent inflammation. Weight and paw 
volume were recorded throughout the dietary regimen. To verify ketosis glucose 
and ketone levels are measured via tail blood and trunk blood respectively. 
Upon sacrificing, two days post injection, blood and paws are collected to assess 
inflammation. Rats were tested for five consecutive days in the order illustrated 
(figure 2). 
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Figure 2. Testing Schedule 
Injection 
Complete Freund’s Adjuvant (CFA) 
All rats were subjected to 100uL of Complete Freund’s 
Adjuvant (CFA) (thermo scientific) in the right hind paw to 
induce the inflammation. CFA as mentioned previously is a 
heat-killed tuberculosis bacteria that causes persistent 
inflammation. 
 
Behavior Tests 
 Spontaneous Pain 
 Spontaneous pain was assessed using the spontaneous foot-lifting model. 
Rats were habituated to the testing room for fifteen minutes prior to being placed 
in an empty plastic cage for thirty minutes. The behavior test was recorded by a 
video camera from underneath the cage. In a blinded analysis of the video each 
hind paw was separately scored on a scale of 0-5 at 10, 15, 20 and 25 minutes for 
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one minute.  
Table 3. Scoring Paradigm for Spontaneous Pain 
 
 
 
 
 
If there was locomotion or grooming at the time intervals listed then the time 
scored was delayed. The spontaneous pain baseline measurement was at 48 
hours prior to the CFA injection, and compared to the 24 hours post injection. 
(Djouhri et al., 2006).  
Tactile Sensitivity - Electrical 
 Nociceptive pain was quantified with an electrical measure of pressure 
using the electronic von Frey (Almemo 2390-5, IITC). The device recorded the 
maximum amount of pressure applied to each hind paw. This was repeated to 
achieve two recordings, which were averaged. 
 
Physiological Measures 
Paw Displacement 
 Paw volume was measured prior to the CFA injection and at 48hours, just 
prior to sacrifice. The paw volume was measured via water displacement using a 
digital analytical balance (Mettler-Toledo) to determine the difference. Paw 
0 paw pressed normally on floor 
1 paw rests lightly on floor, toes ventroflexed 
2 only internal edge of paw pressed to floor 
3 
only heel pressed to floor, hind paw in 
inverted position 
4 whole paw is elevated 
5 animal licks paw 
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volume provides a measurement on the level of physical inflammation of the 
paw.  
Procedures at Sacrifice 
Animals were sacrificed at 48 hours post CFA injection; the rats were 
anesthetized by being exposed to isoflurane in a large glass container. The blood 
glucose level was measured from tail blood by puncturing the tail with a 
hypodermic needle, while ketone (beta-hydroxybutyrate) level was measured 
from trunk blood after decapitation. The blood glucose and ketone levels were 
analyzed using a Precision Xtra glucose/ketone meter strips (Abbott 
Laboratories, Bedford, MA).  
Trunk blood was collected and centrifuged to isolate the plasma and 
frozen for later analysis on the inflammatory markers present. After sacrifice the 
hind paws are amputated at the ankle joint. Paws are weighed on a digital 
analytical balance (Mettler-Toledo). Hindpaw pads are dissected, frozen in liquid 
nitrogen and crushed, and sonicated and repeatedly freeze/thawed to disrupt all 
membranes. After centrifugation, supernatant was tested with an enzyme assay 
for myeloperoxidase, an enzyme contained in neutrophils, the most common 
type of leukocyte. The change of absorbance at 460nm was measured 
spectophotometrically using the myeloperoxidase assay (Bradley et al. 1982). The 
assay combined 0.1mL of the supernatant to 2.9mL of 50mM phosphate buffer, 
pH 6.0, which contained 0.167 mg/mL o-dianisidine dihydrochloride and 
0.0005% hydrogen peroxide (Bradley et al. 1982). 
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Statistical Analysis 
Three independent researchers with two of the three blinded to the diet-
treatment, scored the spontaneous pain. Statistical tests were performed using t-
tests and ANOVA, except in cases of non-normality where we used Wilcoxon 
test. There were no statistical differences in paw weights between rats that 
received two weeks of diet treatment to those who received four weeks, thus the 
data was collapsed across these two groups. P<0.05 was considered significant. 
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RESULTS 
Rats underwent physiological measures (ketone and glucose levels, weight, and 
leukocyte levels) as well as behavioral tests (tactile sensitivity and spontaneous 
pain) to determine whether there was a difference in inflammatory pain between 
KD and CD rats. 
Physiological Results 
Blood Analysis: β –hydroxybutyrate (ketone) & Glucose 
 Trunk blood was collected after decapitation and the β- hydroxybutyrate 
levels were determined by Precision Xtra meters. β-hydroxybutyrate is a ketone 
that indicates ketosis, and was found to be significantly higher in the KD group 
compared to the CD group (Fig. 3A). The glucose levels between the two diet-
groups had no significant difference (Fig. 3B). In prior studies and unpublished 
data we have noticed that as rats age and the longer they adhere to the KD diet 
the more comparable their glucose levels are to rats on a CD, often where they 
difference is insignificant. This data highlights that the rats were in ketosis but 
due to their age on diet onset there is often no change in glucose levels. 
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Body Weight 
 Rats were weighed prior to the CFA injection, if there was a significant 
difference between the body weights of the KD rats versus the CD rats that 
would need to be taken into account for analysis. As depicted (Fig 4) there was 
no significant difference between the body weights and thus the dose of CFA for 
the rat size is consistent as is the paw volume.  
A	 B	
Figure	3.	(A)	KD	rats	had	significantly	higher	 levels	of	β-hydroxybuturate	than	the	CD	rats	 (p<0.001).	 (B)	 Glucose	 levels	were	not	 significantly	 altered	 in	 either	 group.	 (Male	rats,	KD	n=14;	CD	n=10	here	and	in	every	subsequent	figure).	Measurements	were	made	as	described	in	methods.	
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Paw Weight 
 Paws were obtained and weighed on the day of sacrifice, at 48 hours post 
CFA injection. The KD right paws weighed significantly less than the CD (Fig. 5). 
Left paws showed no significant difference between the two diet groups (Fig. 5). 
Figure	4.	There	was	no	significant	difference	in	body	weight	of	rats	on	the	CD	versus	KD	diet	at	the	time	of	CFA	injection.		
Figure	5.	Rats	fed	the	KD	had	significantly	higher	right	paw	weights	than	CD	(p<0.05).	
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Paw Volume  
Paw volume was measured using water displacement prior to CFA 
injection, -24 hours, and post CFA injection, +48 hours. A trend indicating that 
KD had less swollen paws is illustrated; however it did not quite reach 
significance (Fig. 6A). There was no difference found between the left hind paw 
of both diet groups suggesting that the difference is not due to size of the rats but 
due to the KD treatment (Fig. 6B). 
 
Leukocyte Levels Leukocyte	 levels	where	measured	using	 the	myeloperoxidase	assay.	There	was	no	significant	difference	between	the	KD	and	CD	in	the	right	paw	(fig.	7).		
A	 B	
Figure	6.	(A)	KD	rats	had	slightly	lowered	paw	volume	at	48	hours	post	CFA,	the	level	was	not	significant	(p=0.055).	(B)	No	difference	in	paw	volume	between	KD	and	CD.		
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Behavioral Results 
Tactile Sensitivity  
Rats went through tests of tactile sensitivity before and after being injected 
in the right hind paw with heat-killed tuberculosis bacteria to cause 
inflammation. Tactile sensitivity using the electronic von Frey probe did not 
differ between treatment groups before injection, but was strongly increased at 4 
hours post-injection in both treatment groups. In the inflamed paw (right) there 
was a lowered amount of pressure that the KD rats could withstand compared to 
the CD rats. At 48 hr post-injection, sensitivity was no longer significant between 
the KD and CD rats (fig 8A). There were no significant differences in tactile 
sensitivity between the KD and CD in the left paw over the three time periods 
(fig 8B). 
Figure	7.	No	significant	difference	between	the	left	and/or	right	paw	between	the	KD	and	CD	groups	in	myeloperoxidase.		
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Spontaneous Pain 
 Spontaneous pain data illustrates an expected change between each 
specific diet group and the pre and post CFA for the right paw (Fig 9A & 9B). 
This significance illustrates that the CFA was causing a severe inflammation in 
the right paw that debilitated the rats’ usual motor movement. However, there 
was no significant difference across the groups for both prior and post CFA 
injection (Fig. 9A & 9B). There was no significance between the left paw 
treatments (Fig. 9C & 9D). The graphs illustrate the distribution of scores using a 
box and whiskers plot. The top and bottom lines indicate the range of scores, 
while the second line from the top and second line from the bottom illustrate the 
first and third quartile of the data set. The average is the centerline in each box 
plot.
A	 B	
Figure	8.	There	was	no	significant	difference	in	the	tactile	sensitivity	prior	to	the	CFA	injection.	(A)	At	4hr	post	CFA	injection	there	was	a	trend	for	the	KD	rats	to	be	able	to	withstand	more	pressure	to	the	inflamed	paw	(right)	than	the	CD	rats	(p=0.053).	(B)	Left	paw	showed	no	significant	changes	in	response.		
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Figure	9.	There	was	no	significant	difference	in	the	spontaneous	pain	between	KD	and	CD	in	either	the	right	paws	(A	&	B)	or	between	the	left	paws	(C	&	D).	(A)	There	was	a	significant	difference	between	pre-CFA	and	post-CFA	in	the	right	control	paw	(p<0.01).	(B)	Similarly	there	was	a	significant	difference	seen	between	pre-CFA	and	post-CFA	in	the	right	control	paw	(p<0.01).	(C	&	D)	No	significance	seen	in	the	left	paw	between	the	pre-CFA	and	post-CFA	in	either	treatment	group.	
C	 D	
A	 B	
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DISCUSSION 
The effects of the KD on inflammatory pain were analyzed using physiological 
and behavioral techniques. The KD feeding promotes recovery after 
inflammatory insult, however spontaneous pain did not illustrate a reduction in 
nociceptive pain. Paw weights and volumes suggest that the paw is less swollen 
and healing more quickly in rats fed a KD. 
 
Physiological Effects 
Ketone, Glucose and Body Weight  
Our study found significant changes in the impact of KD on ketone levels 
(fig.3A). This was expected, since the rats had been on the KD diet two to four 
weeks. Glucose levels were not significantly altered (fig.3B). Masino and Ruskin 
(2013) report a similar finding that rats had lowered blood glucose shortly after 
starting the KD but at ten weeks there was no noticeable difference in blood 
glucose levels between the KD and control. Previous studies indicate that there 
are strong effects of the KD even when glucose is not significantly different 
(Masino & Ruskin, 2013; Ruskin et al., 2013). Since the body weight was 
consistent between the CD and KD (fig. 4), their paw displacement and paw 
weight is also comparable to determine whether there was a difference of 
inflammation due to diet.  
Paw Weight and Paw Displacement  
Paw weight illustrates a correlation between lowered paw weight and the 
KD (fig. 5), which suggests that the KD reduces swelling in the right hind paw. 
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Paw displacement almost reached significance (fig. 6) further suggesting that the 
KD reduces swelling in the right hind paw. The body weight as mentioned 
previously was not significantly different between the two diet groups, and thus 
we can attribute this difference to paw volume and paw weight, and not to body 
size. Paw size and paw weight depict the amount of swelling that occurred, the 
trend towards lowered paw size and paw weight illustrates the KD may reduce 
inflammation. These results are consistent with a previous study from our lab, 
which found reduced inflammatory swelling and pain in juvenile and adult rats 
on the KD. The specific study conducted by Ruskin et al. (2009) triggered 
nociceptive pain and found a decrease in hind paw swelling in the KD compared 
to the CD. 
 Our lab performed a similar study previously using CFA; only hind paw 
swelling and plasma extravasation was analyzed in both juvenile and adult rats 
(Masino & Ruskin, 2013). Masino and Ruskin (2013) found a larger significance 
between the juvenile rats compared to the adult rats. The results from this 
experiment may have not reached significance but based on this previous study 
we cannot assume there was no effect.  
Leukocyte Levels  
Leukocyte levels were expected to be elevated in the KD right hind-paw 
compared to the CD right hind-paw (fig. 7). A stronger anti-inflammatory 
response is correlated with higher myeloperoxidase levels (Bradley et al. 1982). 
The effect in myeloperoxidase levels between the groups because the CFA dose 
might have been too high creating a ceiling effect that the KD could not rescue 
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the inflammation. Trying a lower dose would help elucidate whether there is 
stronger anti-inflammatory response in one diet group over the other.  
 
Behavioral Effects  
Tactile Sensitivity – Electronic Von Frey Probe 
The responsiveness to tactile pressure was measured using an electronic 
von Frey probe. There was a trend towards reduced nociception four hours post 
CFA injection in the KD rats, as indicated by the very low pressure scores in 
tactile sensitivity (fig. 8). Suggesting that the KD may help reduce pain after 
inflammatory insult, but more testing would need to be performed. The trend 
seen at four hours did not continue at 48-hours post CFA injection (fig. 8). It is 
likely that the inflammatory pain is too strong and that a dietary treatment is not 
able to cause a substantial difference in such a strong effect, thus we suggest 
lowering the CFA dose in future experiments.  
It is important to note some of the caveats with the electronic von Frey. 
Prior to testing the tactile sensitivity with the electronic von Frey, we attempted 
to quantify nociceptive pain using manual force of a von Frey hair. Six probes 
with forces of 2.5, 5.93, 7.79, 21.92, 37, and 51.7g were applied to determine the 
withdrawal reflex (Data not shown). Due to this sequential measure of tactile 
sensitivity using a mechanical von Frey it is suspected that there was likely 
increased sensitivity in both the manual and electronic von Frey measurements. 
Increasing the amount of time between hind paw pokes may decrease the 
variability and the risk of becoming sensitized. If we assume that this probing 
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occurred regularly to the same degree and strength on each paw and animal, 
another caveat that should be considered is the location of the pressure on the 
paw. The location would alter the pressure; although the sensitivity was meant 
to be at the same place each time there will be some variance. Furthermore, 
another caveat is that depending on how the rat is positioned the pressure 
needed to lift the paw varies and thus a lighter pressure may be recorded that is 
not dependent on pain.  
Many of the caveats listed above are problems inherent in manual and 
electronic von Frey testing. However, in future studies we will likely remove 
manual tactile sensitivity, as results were highly variable likely due to increased 
sensitivity. The electronic von Frey seemed to give more consistent measures of 
force.  
Spontaneous Pain 
Spontaneous pain was filmed and later analyzed on a five-point scale 
depending on the movement of each hind paw. Within the KD there was a 
significant difference before and after the CFA injection, similarly seen in the CD 
before and after the CFA injection, exemplifying that the CFA produced a strong 
inflammatory response (fig. 9). The lack in significance may result from the 
difficulty of differentiating between the criteria between the scores in the middle. 
The scoring criteria for 2, 3 and 4 on the spontaneous pain measure differentiated 
between the areas in which pressure was placed on the paw. Distinguishing the 
location of pressure may have caused the scoring to not strongly differentiate 
between the scores for the different diet groups. The results had many zeroes and 
overall the pain scores were relatively low, which caused the graphs to have their 
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distribution close to the x-axis. Finding a clearer way to discern the spontaneous 
pain could illustrate new significance in further studies. Furthermore we suggest 
an earlier time point, as there were more significant trends seen closer to the CFA 
injection. In the future a time point at roughly 6 hours post CFA injection should 
be tried.  
 
Effects of the KD on Inflammatory Pain 
Rats were in ketosis, and any effects seen that differed between the KD 
and CD rats could be attributed to the effects of the KD. Our results indicate that 
the KD may alleviate pain, as there were significant changes indicating lowered 
swelling from the right paw weight. Adding more rats to this study could alter 
the trend to a significant difference between the KD and CD. Specifically, in paw 
displacement and tactile sensitivity we saw a strong trend that may reach 
significance with added rats.  
Though the data on nociception is not quite as definitive, there is a trend 
towards the KD decreasing nociception. Our lab aims to repeat this study by 
adding more rats and altering some of the tests. As mentioned previously we 
believe lowering the amount of CFA and pushing the spontaneous measurement 
forward in the time should be tried in the future. It would be interesting to look 
at juvenile rats, as Ruskin et al (2009) found more consistently significant 
differences in pain in the juvenile KD compared to the adult KD.  
It is likely that multiple mechanisms account for these changes in 
nociception and inflammation, highlighted in the introduction. Our results more 
strongly support a inflammatory mechanism as we see that swelling is reduced 
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through the paw weight and paw displacement than a nociceptive mechanism as 
spontaneous pain had no change, and tactile only had a trend towards 
significance. 
Of the postulated mechanisms of the KD to influence pain (or seizures) 
these data do not disprove most of them. For instance here we have not 
measured GABA levels, vesicular glutamate uptake, mitochondrial profiles, etc. 
We do disprove the glycolytic hypothesis, because of the KD effects that are 
present with a lack of glucose. Our results do seem to support the anti-
inflammatory hypothesis regarding how the KD might be anti-convulsant or 
anti-epileptic.  
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CONCLUSION & FUTURE DIRECTIONS 
The work included in this thesis demonstrates a trend that the KD may 
lower inflammatory pain.  
Our data illustrated that the KD rats had a lowered inflammatory pain at 
four hours post inflammatory insult in the tactile sensitivity measure. There was 
no reduction in nociceptive pain as there were no significant differences in the 
spontaneous pain measure. Physiological measures indicated that rats were in 
ketosis and appeared to have lowered paw volume and weight while body 
weight did not alter suggesting that there may be a reduction in swelling in the 
KD right hind paw. Increasing the number of rats could result in significance in 
some of the tests that had close significance.  
In an attempt to further discern whether the KD may aid in pain relief, 
other models of pain should be studied. An arthritic model or an inflammatory 
bowel disease model could be used to further study the effect of KD on 
inflammatory diseases. Studying a different diet such as an MCT diet, which has 
been shown to be easily metabolized and therapeutically effective in epilepsy 
could be very beneficial to determine whether there are stronger effects than seen 
in the KD. Another dietary regimen that should be pursued is calorie restriction, 
which is anti-inflammatory (Shibolet et al., 2002). 
The present results suggests that more data is needed to determine 
whether the KD can help alleviate pain and reduce inflammation, however taken 
together with previous studies it offers a promising avenue for pain alleviation 
that should be pursued.  
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Clinical work with the KD is still very minimal but could offers a wide set 
of benefits as there are no side effects and very minimal cost. Alleviating pain 
through an effective and non-pharmaceutical approach is extremely valuable for 
millions of individuals suffering from either chronic pain or who would like to 
use alternative medicine. Thus, focusing research on alleviating pain through a 
dietary regimen or metabolic strategy could be extremely advantageous.  
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